Cite
Bégin P, Dominguez T, Wilson SP, et al. Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using Omalizumab. Allergy Asthma Clin Immunol. 2014;10(1):7doi: 10.1186/1710-1492-10-7.
Bégin, P., Dominguez, T., Wilson, S. P., Bacal, L., Mehrotra, A., Kausch, B., Trela, A., Tavassoli, M., Hoyte, E., O'Riordan, G., Blakemore, A., Seki, S., Hamilton, R. G., & Nadeau, K. C. (2014). Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using Omalizumab. Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology, 10(1), 7. https://doi.org/10.1186/1710-1492-10-7
Bégin, Philippe, et al. "Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using Omalizumab." Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology vol. 10,1 (2014): 7. doi: https://doi.org/10.1186/1710-1492-10-7
Bégin P, Dominguez T, Wilson SP, Bacal L, Mehrotra A, Kausch B, Trela A, Tavassoli M, Hoyte E, O'Riordan G, Blakemore A, Seki S, Hamilton RG, Nadeau KC. Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using Omalizumab. Allergy Asthma Clin Immunol. 2014 Feb 20;10(1):7. doi: 10.1186/1710-1492-10-7. PMID: 24576338; PMCID: PMC3936817.
Copy
Download .nbib